Log in

NASDAQ:RDUSRadius Health Stock Price, Forecast & News

$12.72
-0.52 (-3.93 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.46
Now: $12.72
$13.31
50-Day Range
$11.85
MA: $14.15
$17.47
52-Week Range
$10.32
Now: $12.72
$29.97
Volume358,848 shs
Average Volume690,038 shs
Market Capitalization$590.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.16
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
Radius Health logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDUS
CUSIPN/A
Phone617-551-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$173.32 million
Book Value($1.60) per share

Profitability

Net Income$-132,990,000.00

Miscellaneous

Employees398
Market Cap$590.08 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

How has Radius Health's stock been impacted by COVID-19 (Coronavirus)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RDUS shares have decreased by 20.8% and is now trading at $12.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Radius Health?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Radius Health.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Radius Health.

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.09. The biopharmaceutical company had revenue of $47.92 million for the quarter, compared to analysts' expectations of $46.77 million. Radius Health had a negative net margin of 66.82% and a negative return on equity of 929.94%. View Radius Health's earnings history.

What guidance has Radius Health issued on next quarter's earnings?

Radius Health updated its FY 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $190-220 million, compared to the consensus revenue estimate of $225.56 million.

What price target have analysts set for RDUS?

9 Wall Street analysts have issued twelve-month price objectives for Radius Health's shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate Radius Health's stock price to reach $29.38 in the next year. This suggests a possible upside of 130.9% from the stock's current price. View analysts' price targets for Radius Health.

Has Radius Health been receiving favorable news coverage?

News headlines about RDUS stock have been trending extremely negative on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Radius Health earned a coverage optimism score of -4.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutRadius Health.

Who are some of Radius Health's key competitors?

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), EXACT Sciences (EXAS), Cara Therapeutics (CARA), Amarin (AMRN), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Netflix (NFLX), ACADIA Pharmaceuticals (ACAD) and Micron Technology (MU).

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
  • Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
  • Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Brian Nicholas Harvey, Advisor (Age 58)
  • Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (5.04%), Emerald Mutual Fund Advisers Trust (1.61%), Geode Capital Management LLC (1.45%), Nuveen Asset Management LLC (1.19%), Two Sigma Advisers LP (1.05%) and Pictet Asset Management Ltd. (0.92%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere. View institutional ownership trends for Radius Health.

Which major investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Mackay Shields LLC, First Trust Advisors LP, Two Sigma Investments LP, Spark Investment Management LLC, Chicago Equity Partners LLC, Tudor Investment Corp Et Al, Congress Park Capital LLC, and Squarepoint Ops LLC. View insider buying and selling activity for Radius Health.

Which major investors are buying Radius Health stock?

RDUS stock was acquired by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Nuveen Asset Management LLC, Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., Janus Henderson Group PLC, Pictet Asset Management Ltd., Two Sigma Advisers LP, and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech. View insider buying and selling activity for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $12.72.

How big of a company is Radius Health?

Radius Health has a market capitalization of $590.08 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

What is Radius Health's official website?

The official website for Radius Health is www.radiuspharm.com.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.